The FDA said it does not intend to regulate the Genzyme Tissue Repair division's Carticel cartilage cell service at this time, but has decided to hold a meeting Nov. 16 and 17 to consider the public health impact of such products and possible regulatory approaches to autologous cells manipulated ex vivo and intended for structural